Tenderwize
Retour à la recherche

Non-exclusive Drug Discount Agreement for Flecainide

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jan 31, 2028 · 521 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Flecainid (ATC-Code nach WHO: C01BC04)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No minimum volume commitment; actual demand depends on physician prescribing and patient needs. Revenue cannot be predi...

The buyer may terminate the Open House if exclusive agreements are concluded, which typically occurs 8-12 months after...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Supply of pharmaceutical products containing Flecainide (ATC C01BC04) under a non-exclusive discount agreement.
  • No minimum purchase quantities guaranteed.
Afficher le résumé complet

This notice announces a non-exclusive drug discount agreement (Rabattvereinbarung) under § 130a Abs. 8 SGB V for the active substance Flecainide (ATC C01BC04), conducted as an Open House model. The contract is with AOK PLUS for the regions Saxony and Thuringia. There is no guaranteed volume, no exclusivity, and no individual negotiations. The agreement runs until 31 January 2028. Participation is open to all interested pharmaceutical companies that meet the eligibility criteria.

Risques

No minimum volume commitment; actual demand depends on physician prescribing and patient needs. Revenue cannot be predi...

The buyer may terminate the Open House if exclusive agreements are concluded, which typically occurs 8-12 months after...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Participants must be pharmaceutical companies within the meaning of § 4 Abs. 18 AMG for the offered medicinal products.
  • The company must have its registered office within the scope of the AMG, EU member state, or EEA.

Eligibility

  • Declaration of no exclusion grounds under §§ 123, 124 GWB (using provided form).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Flecainide

Non-exclusive discount agreement for pharmaceutical products containing the active substance Flecainide. Open House model with no exclusivity or guaranteed volumes. Agreement ends 31 January 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Détails de la procédure

Date de publication
07 Oct 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
660388-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30